Results of a preclinical study demonstrate the feasibility of implanting a next-generation injectable version of a telescope prosthesis for end-stage macular degeneration and suggest it has promising advantages for improving surgical ease and safety.
A new foldable hydrophobic acrylic one-piece IOL provided good visual acuity to patients in a small pilot study with a short follow-up period.
Nidek has received FDA 510(k) clearance for a non-mydriatic automated fundus camera (AFC-330) that it will market to the U.S. ophthalmology market and Marco Ophthalmic will market to the optometry market.
Understanding the cause of elevated IOP in patients with uveitis is the basis for developing a rational treatment plan.
As outgoing president of the ASCRS, Edward J. Holland, MD, can be recognized for a number of accomplishments and the introduction of several new initiatives.
Many agents have been investigated in clinical trials for neuroprotection in glaucoma, but none has proven efficacy, and so IOP control continues to be the mainstay strategy for preventing glaucoma progression.
Using interferon alpha-2b systemically for the treatment of refractory uveitic cystoid macular edema may be helpful in carefully selected patients.
The corrections following phacoemulsification and IOL implantation that are achievable today are a far cry from those commanded in the 1970s when 20/40 corrected bilaterally was considered an accomplishment following implantation of the early IOLs.
As a rule, the latest and greatest new technology first becomes available to the haves in this world, and only much later, if at all, to the have-nots.
Epimacular brachytherapy was described as "interesting and encouraging" at the 2-year time point for treating exudative age-related macular degeneration that had been previously treated with anti-vascular endothelial growth factor injections.